Jim Simons
AXSM icon

Jim Simons’s Axsome Therapeutics AXSM Stock Holding History

Jim Simons’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.1M Buy
262,000
+97,700
+59% +$21.2M 0.09% 255
2026
Q1 		$27.8M Sell
164,300
-5,700
-3% -$985K 0.04% 526
2025
Q4 		$31M Buy
170,000
+20,000
+13% +$2.79M 0.05% 438
2025
Q3 		$18.2M Buy
150,000
+11,300
+8% +$1.27M 0.02% 769
2025
Q2 		$14.5M Buy
138,700
+4,300
+3% +$455K 0.02% 866
2025
Q1 		$15.7M Buy
+134,400
New +$15.3M 0.02% 769
2020
Q3 		– Sell
-66,400
Closed -$5.46M – 3368
2020
Q2 		$5.46M Buy
66,400
+14,300
+27% +$1.1M ﹤0.01% 1590
2020
Q1 		$3.06M Buy
52,100
+1,330
+3% +$108K ﹤0.01% 1833
2019
Q4 		$5.25M Buy
+50,770
New +$2.05M ﹤0.01% 1821
2019
Q3 		– Sell
-247,200
Closed -$6.36M – 3422
2019
Q2 		$6.36M Buy
+247,200
New +$4.95M 0.01% 1680
2019
Q1 		– Sell
-15,110
Closed -$43K – 3443
2018
Q4 		$43K Buy
+15,110
New +$49.7K ﹤0.01% 3296
2018
Q1 		– Sell
-48,400
Closed -$271K – 3363
2017
Q4 		$271K Buy
+48,400
New +$244K ﹤0.01% 3049

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jim Simons's AXSM Position: Q2 2026 in Review

Jim Simons increased its Axsome Therapeutics (AXSM) stake by 59% in Q2 2026, buying an estimated $21.2M and bringing the position to 262,000 shares worth $64.1M. The position accounts for 0.09% of the portfolio, ranked #255.

Jim Simons first reported a position in AXSM in Q4 2017 and has held it in 12 quarters since. 507 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Jim Simons held 262,000 shares of Axsome Therapeutics worth $64.1M as of Q2 2026.
  • Jim Simons bought 97,700 Axsome Therapeutics shares in Q2 2026, an estimated $21.2M.
  • Axsome Therapeutics made up 0.09% of Jim Simons's portfolio in Q2 2026, its #255 holding.
  • Jim Simons first reported a position in Axsome Therapeutics in Q4 2017 and has held it in 12 quarters since.
  • 507 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.